In this week's podcast edition of Five Must-Know Things: Merck & Co’s Modifi acquisition; scenarios for new obesity drugs; Astellas gets US approval for claudin drug Vyloy; iTeos builds TIGIT lead; and execs discuss AI in clinical trials.
In this week's podcast edition of Five Must-Know Things: J&J looks to Tremfya as Stelara declines; Pfizer’s Hympavzi may find hemophilia B niche; big pharma’s cell and gene therapy realities; M&A took a holiday in Q3; and last rites for Sanofi’s RIPK1 drug.
Dexter Yan talks about his September interview with Sharon Barr, AstraZeneca’s executive vice president, Biopharmaceuticals R&D. Hu Xu shares her articles on Sciwind’s ecnoglutide Phase III results and a Chinese law firm’s view on the proposed US BIOSECURE Act.
In this week's podcast edition of Five Must-Know Things: making cell and gene therapies more accessible; Roche’s obesity plans; BIOSECURE and Indian firms; IPOs begin to recover; and Nxera looks to the future.
In this week's podcast edition of Five Must-Know Things: J&J interested in differentiated obesity assets; Kerendia hits in heart failure; strong HERCULES data keep Sanofi’s MS plans alive; WCLC preview; and Mankind sets eyes on 5x growth.
In this week's podcast edition of Five Must-Know Things: summer ADC dealmaking continues apace; a look at cell therapies in Japan; Pfizer’s new US digital consumer platform; Galapagos’s US point of care CAR-T study; and Novartis partners with Lindy on biologics delivery.
In this week's podcast edition of Five Must-Know Things: CMS’s price reveal better than expected?; new diabetes risk data for Zepbound; can J&J’s lung cancer combo stand up to Tagrisso?; new recruits for BioMarin leadership; and Glenmark’s shifting revenues.
